Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Monotherapy
100%
Systematic Meta-analysis
100%
Meta-analysis of Randomized Controlled Trials
100%
Pioglitazone
100%
Blood Pressure
33%
Type 2 Diabetes Mellitus Patients
33%
Meta-analysis
22%
Fasting Plasma Glucose
22%
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
22%
Clinical Practice
11%
Randomized Controlled Trial
11%
Therapeutic Potential
11%
Hypertension
11%
Adverse Events
11%
Insulin Resistance
11%
Adverse Effects
11%
Effective Treatment
11%
RevMan
11%
Edema
11%
Lipid Metabolism
11%
Treatment Options
11%
High-density Lipoprotein Cholesterol (HDL-C)
11%
Hyperglycemia
11%
Drug Choice
11%
Random Effects Model
11%
Insulin Sensitizers
11%
Hypoglycemia Risk
11%
Triglyceride Level
11%
Dyslipidemia
11%
Hemoglobin A1c (HbA1c)
11%
Thiazolidinediones
11%
Patient Needs
11%
Oral Antidiabetic Drugs
11%
Lipid Parameters
11%
Glycated Hemoglobin A1c
11%
History of Cardiovascular Disease
11%
Safety Outcomes
11%
Lipoprotein Levels
11%
Weighted Model
11%
R Software
11%
Increased Body Weight
11%
Software-based
11%
Metafor Package
11%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Monotherapy
100%
Non Insulin Dependent Diabetes Mellitus
100%
Pioglitazone
100%
Insulin Resistance
22%
Hemoglobin A1c
22%
Adverse Event
11%
Cardiovascular Disease
11%
Triacylglycerol
11%
High Density Lipoprotein
11%
Hypoglycemia
11%
Dyslipidemia
11%
Edema
11%
Hyperglycemia
11%
Random Effects Model
11%
Glycosylated Hemoglobin
11%
Oral Antidiabetic Agent
11%
Thiazolidinedione
11%